Fig. 2: Post-treatment survival of JAK2 inhibitor-naive patients with myelofibrosis receiving JAK2 inhibitors in the context of clinical trials and informative for high-risk mutations. | Blood Cancer Journal

Fig. 2: Post-treatment survival of JAK2 inhibitor-naive patients with myelofibrosis receiving JAK2 inhibitors in the context of clinical trials and informative for high-risk mutations.

From: Determinants of survival and retrospective comparisons of 183 clinical trial patients with myelofibrosis treated with momelotinib, ruxolitinib, fedratinib or BMS- 911543 JAK2 inhibitor

Fig. 2: Post-treatment survival of JAK2 inhibitor-naive patients with myelofibrosis receiving JAK2 inhibitors in the context of clinical trials and informative for high-risk mutations.

a Post-treatment survival of 124 JAK2 inhibitor-naive patients with myelofibrosis receiving JAK2 inhibitors in the context of clinical trials and informative for high-risk mutations, stratified by HR-weighted scoring system. b Post-treatment survival of 166 JAK2 inhibitor-naive patients with myelofibrosis receiving JAK2 inhibitors in the context of clinical trials and evaluable for spleen response, stratified by spleen response. c Post-treatment survival of 66 JAK2 inhibitor-naive patients with myelofibrosis receiving JAK2 inhibitors in the context of clinical trials and transfusion-dependent anemia, stratified by anemia response.

Back to article page